Press Releases

 
Press Releases
  Date Title and Summary View
Mar 17, 2017
FREMONT, Calif., March 17, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), an emerging CNS company focusing on developing an acute migraine treatment with a differentiated efficacy profile using the Company's proprietary transdermal delivery system, today announced the pricing of an underwritten public offering o...
Mar 1, 2017
FREMONT, Calif., March 01, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), an emerging central nervous system company focused on providing symptom relief to patients using the Company's proprietary intracutaneous delivery system, today announced financial results for the fourth quarter and year ended December 3...
Feb 13, 2017
41.5% of patients experienced freedom from pain at 2 hours vs. 14.3% for placebo (p 68.3% of patients experienced freedom from most bothersome symptom at 2 hours vs. 42.9% for placebo (p 26.8% of patients experienced freedom from pain at 1 hour vs. 10.4% ...
Jan 23, 2017
FREMONT, Calif., Jan. 23, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), an emerging CNS company focusing on providing rapid symptom relief to patients using the Company's proprietary transdermal delivery system, today announced that it has approved an inducement grant of options to purchase 35,000 shares of the Company's ...
Jan 5, 2017
FREMONT, Calif., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), an emerging CNS company focused on providing rapid symptom relief to patients using the Company's proprietary intracutaneous delivery system, today announced that the last subject has been treated in the Company's registration-enabling, pivotal effica...
Nov 22, 2016
FREMONT, Calif., Nov. 22, 2016 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), an emerging central nervous system company focused on providing rapid symptom relief to patients using the Company's proprietary intracutaneous delivery system, today announced that it has sold all of its interest in Zosano, Inc. for an aggregate cash...
Nov 9, 2016
FREMONT, Calif., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), an emerging central nervous system company focused on providing rapid symptom relief to patients using the Company's proprietary intracutaneous delivery system, today announced financial results for the third quarter ended September 30, 201...
Nov 8, 2016
FREMONT, Calif., Nov. 08, 2016 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), an emerging CNS company focused on providing rapid symptom relief to patients using the Company's proprietary intracutaneous delivery system, today announced completion of enrollment in its registration-enabling, pivotal efficacy trial (the Zotrip tri...
Sep 9, 2016
FREMONT, Calif., Sept. 09, 2016 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), an emerging CNS company focusing on providing rapid symptom relief to patients using the Company's proprietary transdermal delivery system, today announced that it has approved an inducement grant of options to purchase 252,000 shares of t...
Sep 8, 2016
FREMONT, Calif., Sept. 08, 2016 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), an emerging CNS company focusing on providing rapid symptom relief to patients using the Company's proprietary transdermal delivery system, today announced the appointment of Ms. Georgia Erbez as its Chief Business Officer, effective September...
Page: FirstPrevious
2
... NextLast
= add release to Briefcase